ADA 25: MariTide Treatment for Obesity in Patients with or without Type 2 Diabetes
A six-minute clinical trialist summary of the phase 2 results for MariTide, a once-monthly investigational obesity medication, covering weight loss, HbA1c, side effects and next steps.
With Dr. Harold Ba
Key moments
Tap a moment to play the video from there.
- 0:00Speaker and program backgroundDr. Ba introduces himself as a clinical trialist and says he was an investigator in the MariTide development program.
- 0:30How MariTide is builtBa explains that it pairs a GIP receptor antibody with a GLP-1 receptor agonist peptide, and what the name's two parts refer to.
- 1:01Phase 2 trial designHe describes a double blind, placebo controlled, dose ranging study of 592 people with obesity, with and without type 2 diabetes.
- 1:31Top dose and weight resultsBa stresses this is phase 2 and then reports placebo corrected weight reduction at 420 milligrams every four weeks, around 17% without diabetes.
- 2:01Results in type 2 diabetesHe cites around 15% placebo corrected weight reduction with diabetes and says the usual gap between the two groups was smaller here.
- 2:31HbA1c and lean massBa reports a 2.2% reduction in hemoglobin A1C in the diabetes group and says less than one third of weight lost was lean body mass.
- 3:01Side effects and no escalationHe says side effects were frequent and mostly gastrointestinal, and that many participants received their assigned dose from the start without escalation.
- 4:05Take-home message for cliniciansBa calls the weight loss results strong and notes monthly dosing, but says the side effects need to be improved.
- 5:35Future research on dosingHe hopes phase 3 research will identify a dose escalation strategy that eases gastrointestinal effects without reducing effectiveness.
What the video says
This short Radcliffe Cardiology piece, recorded around the American Diabetes Association meeting, features Dr. Harold Ba. He is medical director and president of a metabolic research center in Louisville, Kentucky, and says he was an investigator in the MariTide development program. He answers questions about the phase 2 trial, which he says was published in the New England Journal of Medicine.
He first describes what the compound is. According to Ba, MariTide, also called AMG133, joins an antibody against the GIP receptor to a GLP-1 receptor agonist peptide. He explains the name this way: the "tide" part is the peptide and the other part is the antibody. He describes the study as a phase 2, double blind, randomized, placebo controlled, dose ranging trial of 592 people with obesity, some of whom also had type 2 diabetes.
The efficacy figures are the core of the talk. Ba says that at the top dose of 420 milligrams every four weeks, placebo corrected weight loss was around 17% in people with obesity and no diabetes, and around 15% in those who had type 2 diabetes. He notes that people with diabetes often respond less well in trials, and that the gap here was smaller. In the diabetes group he reports a 2.2% fall in hemoglobin A1C, and he says less than one third of the weight lost was lean body mass.
Ba is equally direct about tolerability. He says side effects were frequent and mostly gastrointestinal. Many participants, particularly those with diabetes, started straight on their assigned dose with no dose escalation, which he describes as unusual for newer obesity medications. The team did this because they did not know whether escalation was needed.
His take-home message for clinicians is that weight loss looks strong and the once-monthly schedule is a possible advantage, but tolerability needs work. He hopes phase 3 trials will test a dose escalation strategy to reduce gastrointestinal effects, and says he does not expect that to reduce effectiveness, though this is not yet known.
On each compound
MariTide0:30
Ba describes MariTide (AMG133) as a GIP receptor antibody linked to a GLP-1 receptor agonist peptide, given as a once-monthly subcutaneous injection. He reports around 17% placebo corrected weight reduction without diabetes and around 15% with type 2 diabetes at 420 milligrams every four weeks, along with frequent, mostly gastrointestinal side effects.
See how your DNA reads MariTideWhat this video doesn’t settle
- All figures are from a phase 2 trial that Ba himself says informs, but does not replace, phase 3 evidence, and he is an investigator in the program.
- The video gives no numbers for how common or severe the gastrointestinal side effects were, only that they were frequent.
- Ba says he does not expect dose escalation to reduce effectiveness, but he does not know yet whether it will lessen side effects.
Questions this video answers
What is MariTide and how is it built?
According to Dr. Ba, MariTide, also called AMG133, combines an antibody against the GIP receptor with a GLP-1 receptor agonist peptide. He describes it as an investigational obesity medication given once a month.
How much weight did people lose in the MariTide phase 2 trial?
Ba says that at 420 milligrams every four weeks, placebo corrected weight reduction was around 17% in people with obesity and no diabetes. In people with type 2 diabetes it was around 15%. He stresses these are phase 2 results.
What side effects of MariTide does the speaker mention?
Ba says side effects in the phase 2 study were frequent and mostly gastrointestinal. He notes that many participants started on their assigned dose without escalation, and he hopes a dose escalation approach in phase 3 can reduce these effects.
Did MariTide change HbA1c or lean body mass in the trial?
Ba reports a 2.2% reduction in hemoglobin A1C among participants with type 2 diabetes. He also says less than one third of the weight lost was lean body mass.
Video by Radcliffe Cardiology on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
